185 related articles for article (PubMed ID: 34771730)
1. Faecal Diagnostic Biomarkers for Colorectal Cancer.
Cruz A; Carvalho CM; Cunha A; Crespo A; Iglesias Á; García-Nimo L; Freitas PP; Cubiella J
Cancers (Basel); 2021 Nov; 13(21):. PubMed ID: 34771730
[TBL] [Abstract][Full Text] [Related]
2. A combination of faecal tests for the detection of colon cancer: a new strategy for an appropriate selection of referrals to colonoscopy? A prospective multicentre Italian study.
Parente F; Marino B; Ilardo A; Fracasso P; Zullo A; Hassan C; Moretti R; Cremaschini M; Ardizzoia A; Saracino I; Perna F; Vaira D
Eur J Gastroenterol Hepatol; 2012 Oct; 24(10):1145-52. PubMed ID: 22735608
[TBL] [Abstract][Full Text] [Related]
3. Faecal biomarkers do not always identify pre-cancerous lesions in patients who present in primary care with bowel symptoms.
Keenan J; Aitchison A; Leaman J; Pearson J; Frizelle F
N Z Med J; 2019 Aug; 132(1501):48-56. PubMed ID: 31465327
[TBL] [Abstract][Full Text] [Related]
4. Faecal pyruvate kinase isoenzyme type M2 for colorectal cancer screening: a meta-analysis.
Tonus C; Sellinger M; Koss K; Neupert G
World J Gastroenterol; 2012 Aug; 18(30):4004-11. PubMed ID: 22912551
[TBL] [Abstract][Full Text] [Related]
5. Faecal haemoglobin can define risk of colorectal neoplasia at surveillance colonoscopy in patients at increased risk of colorectal cancer.
Digby J; Cleary S; Gray L; Datt P; Goudie DR; Steele RJC; Strachan JA; Humphries A; Fraser CG; Mowat C
United European Gastroenterol J; 2020 Jun; 8(5):559-566. PubMed ID: 32213041
[TBL] [Abstract][Full Text] [Related]
6. Tumor pyruvate kinase isoenzyme type M2 and immunochemical fecal occult blood test: performance in screening for colorectal cancer.
Mulder SA; van Leerdam ME; van Vuuren AJ; Francke J; van Toorenenbergen AW; Kuipers EJ; Ouwendijk RJ
Eur J Gastroenterol Hepatol; 2007 Oct; 19(10):878-82. PubMed ID: 17873612
[TBL] [Abstract][Full Text] [Related]
7. Power of screening tests for colorectal cancer enhanced by high levels of M2-PK in addition to FOBT.
Zaccaro C; Saracino IM; Fiorini G; Figura N; Holton J; Castelli V; Pesci V; Gatta L; Vaira D
Intern Emerg Med; 2017 Apr; 12(3):333-339. PubMed ID: 28155016
[TBL] [Abstract][Full Text] [Related]
8. Comparison of faecal M2-PK and FIT in a population-based bowel cancer screening cohort.
Leen R; Seng-Lee C; Holleran G; O'Morain C; McNamara D
Eur J Gastroenterol Hepatol; 2014 May; 26(5):514-8. PubMed ID: 24699725
[TBL] [Abstract][Full Text] [Related]
9. Comparison of faecal protein biomarkers' diagnostic accuracy for colorectal advanced neoplasms: a systematic review and meta-analysis.
Nasir Kansestani A; Zare ME; Tong Q; Zhang J
Sci Rep; 2022 Feb; 12(1):2623. PubMed ID: 35173276
[TBL] [Abstract][Full Text] [Related]
10. Reduction of faecal immunochemical test false-positive results using a signature based on faecal bacterial markers.
Malagón M; Ramió-Pujol S; Serrano M; Serra-Pagès M; Amoedo J; Oliver L; Bahí A; Mas-de-Xaxars T; Torrealba L; Gilabert P; Miquel-Cusachs JO; García-Nimo L; Saló J; Guardiola J; Piñol V; Cubiella J; Castells A; Aldeguer X; Garcia-Gil J
Aliment Pharmacol Ther; 2019 Jun; 49(11):1410-1420. PubMed ID: 31025420
[TBL] [Abstract][Full Text] [Related]
11. Faecal immunochemical tests to triage patients with lower abdominal symptoms for suspected colorectal cancer referrals in primary care: a systematic review and cost-effectiveness analysis.
Westwood M; Corro Ramos I; Lang S; Luyendijk M; Zaim R; Stirk L; Al M; Armstrong N; Kleijnen J
Health Technol Assess; 2017 May; 21(33):1-234. PubMed ID: 28643629
[TBL] [Abstract][Full Text] [Related]
12. Colorectal cancer detection in an asymptomatic population: fecal immunochemical test for hemoglobin vs. fecal M2-type pyruvate kinase.
Caviglia GP; Cabianca L; Fagoonee S; Gili FM
Biochem Med (Zagreb); 2016; 26(1):114-20. PubMed ID: 26981025
[TBL] [Abstract][Full Text] [Related]
13. A pilot study on faecal MMP-9: a new noninvasive diagnostic marker of colorectal cancer.
Annaházi A; Ábrahám S; Farkas K; Rosztóczy A; Inczefi O; Földesi I; Szűcs M; Rutka M; Theodorou V; Eutamene H; Bueno L; Lázár G; Wittmann T; Molnár T; Róka R
Br J Cancer; 2016 Mar; 114(7):787-92. PubMed ID: 26908323
[TBL] [Abstract][Full Text] [Related]
14. Sensitivity and specificity of faecal tumour M2 pyruvate kinase for detection of colorectal adenomas in a large screening study.
Haug U; Hundt S; Brenner H
Br J Cancer; 2008 Jul; 99(1):133-5. PubMed ID: 18542075
[TBL] [Abstract][Full Text] [Related]
15. Fecal occult blood test for colorectal cancer screening: an evidence-based analysis.
Medical Advisory Secretariat
Ont Health Technol Assess Ser; 2009; 9(10):1-40. PubMed ID: 23074514
[TBL] [Abstract][Full Text] [Related]
16. Serum M2-pyruvate kinase: A promising non-invasive biomarker for colorectal cancer mass screening.
Meng W; Zhu HH; Xu ZF; Cai SR; Dong Q; Pan QR; Zheng S; Zhang SZ
World J Gastrointest Oncol; 2012 Jun; 4(6):145-51. PubMed ID: 22737276
[TBL] [Abstract][Full Text] [Related]
17. Biomarkers for detecting colorectal cancer non-invasively: DNA, RNA or proteins?
Loktionov A
World J Gastrointest Oncol; 2020 Feb; 12(2):124-148. PubMed ID: 32104546
[TBL] [Abstract][Full Text] [Related]
18. Detection of Chitinase 3-Like 1 in Symptomatic Primary Care Patient Faecal Samples is Not a Reliable Biomarker of Colonic Lesions.
Keenan JI; Aitchison A; Frizelle FA; Hock BD
Asian Pac J Cancer Prev; 2023 Jul; 24(7):2289-2293. PubMed ID: 37505758
[TBL] [Abstract][Full Text] [Related]
19. Early Detection of Colorectal Cancer: a Multi-Center Pre-Clinical Case Cohort Study for Validation of a Combined DNA Stool Test.
Dollinger MM; Behl S; Fleig WE
Clin Lab; 2018 Oct; 64(10):1719-1730. PubMed ID: 30336540
[TBL] [Abstract][Full Text] [Related]
20.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
[Next] [New Search]
